Recent Advances in the Treatment of Opioid Use Disorder
Purpose of Review Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States’ healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy. Recent Findings Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments’ market viability. Summary This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
Current Review of Pain - 25(2021), 4 vom: 11. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kuppalli, Sumanth [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
doi: |
10.1007/s11916-021-00941-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR04345478X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR04345478X | ||
003 | DE-627 | ||
005 | 20230520011518.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210311s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11916-021-00941-8 |2 doi | |
035 | |a (DE-627)SPR04345478X | ||
035 | |a (DE-599)SPRs11916-021-00941-8-e | ||
035 | |a (SPR)s11916-021-00941-8-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kuppalli, Sumanth |e verfasserin |4 aut | |
245 | 1 | 0 | |a Recent Advances in the Treatment of Opioid Use Disorder |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose of Review Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States’ healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy. Recent Findings Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments’ market viability. Summary This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment. | ||
650 | 4 | |a Opioids |7 (dpeaa)DE-He213 | |
650 | 4 | |a Substance abuse |7 (dpeaa)DE-He213 | |
650 | 4 | |a Opioid epidemic |7 (dpeaa)DE-He213 | |
650 | 4 | |a Opioid use disorder |7 (dpeaa)DE-He213 | |
700 | 1 | |a Seth, Raghav |e verfasserin |4 aut | |
700 | 1 | |a Orhurhu, Vwaire |e verfasserin |4 aut | |
700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
700 | 1 | |a Kaye, Alan D. |e verfasserin |4 aut | |
700 | 1 | |a Hunter, Corey |e verfasserin |4 aut | |
700 | 1 | |a Gulati, Amitabh |e verfasserin |4 aut | |
700 | 1 | |a Adekoya, Peju |e verfasserin |4 aut | |
700 | 1 | |a Kaye, Adam M. |e verfasserin |4 aut | |
700 | 1 | |a Jones, Mark R. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current Review of Pain |d Current Medicine Group, 1998 |g 25(2021), 4 vom: 11. März |w (DE-627)SPR023001666 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2021 |g number:4 |g day:11 |g month:03 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11916-021-00941-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 25 |j 2021 |e 4 |b 11 |c 03 |